MedTrace Logo

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

NCT04008524 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-08-06

No results posted yet for this study

Summary

This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.

Conditions

  • Relapsed and Refractory Hematological Malignancies

Interventions

BIOLOGICAL

CAR-T cells

Chimeric Antigen Receptor-T cells

Sponsors & Collaborators

  • Juventas Cell Therapy Ltd.

    collaborator INDUSTRY

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008524 on ClinicalTrials.gov